Advertisement
Screener

Perrigo Company plc (PRGO) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.3 / 5 stars · 28/110 Roast Me

Perrigo Company plc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Perrigo Company plc (PRGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.80% for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2021-03-01

  • Perrigo Company plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-09-27 was 0.30%.
  • Perrigo Company plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.80%, a 11.11% decline from fiscal 2017.
  • Perrigo Company plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.90%, a 80.00% increase from fiscal 2016.
  • Perrigo Company plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.50%.
  • Perrigo Company plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.30%, a 0.00% change from fiscal 2014.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2018-12-310.80%
10-K · filed 2021-03-01
2017-12-310.90%
10-K · filed 2020-02-27
2016-12-310.50%
10-K · filed 2019-02-27
2015-06-270.30%
10-K · filed 2018-03-01
2014-09-270.30%
10-K · filed 2014-08-14
2014-06-280.30%
10-K · filed 2017-05-22
2013-06-290.30%
10-KT · filed 2016-02-25
2012-06-300.40%
10-K · filed 2014-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Generate Biomedicines, Inc. (GENB)United States$2.052B
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38